Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Version updated to v3.0.2, replacing v3.0.1; the old NSCLC trial reference and the Back to Top element were removed, with no substantive core-content changes.
    Difference
    1%
    Check dated 2025-09-13T17:42:00.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.2%
    Check dated 2025-09-06T15:26:49.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated to include new drug information and a revised facility name and location, while some previous drug information and location details have been removed.
    Difference
    5%
    Check dated 2025-08-30T12:09:55.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page has added information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, referencing a specific study published in the New England Journal of Medicine.
    Difference
    0.6%
    Check dated 2025-08-23T08:01:27.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to a new version (v2.16.12), while a specific reference to a randomized trial on non-small-cell lung cancer has been removed.
    Difference
    0.9%
    Check dated 2025-08-16T04:50:06.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The page has been updated to include information about Pembrolizumab for the treatment of non-small-cell lung cancer, indicating a significant addition to the core content.
    Difference
    0.6%
    Check dated 2025-08-09T00:18:49.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.